---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-001710"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:40:14.602278+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix: 2022 Dextenza revenue est. $50.2M (+20% YoY); cash $102.3M; pipeline on track

## Summary
- Dextenza net product revenue: Q4 2022 est. $13.6M (14% seq., 11% YoY); FY2022 est. $50.2M (20% YoY).
- Preliminary cash and equivalents $102.3M as of Dec 31, 2022; sufficient to fund operations through mid-2024.
- OTX-TKI wet AMD Phase 1: 9- and 10-month data at Angiogenesis Feb 2023; potential Phase 2/3 start Q3 2023 subject to funding.
- Phase 1 diabetic retinopathy trial initiated Dec 2022; OTX-TIC glaucoma Phase 2 top-line data expected Q4 2023.

## SEC filing metadata
- accession: 0001104659-23-001710
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923001710/0001104659-23-001710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923001710/tm232417d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-001710
- JSON: https://secwatch.observer/filing/0001104659-23-001710.json
- Plain text: https://secwatch.observer/filing/0001104659-23-001710.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2022 results: revenue net product revenue for the fourth quarter of 2022 is estimated to be $13.6 million.
  - Period: the quarter and year ended December 31, 2022
  - Revenue: net product revenue for the fourth quarter of 2022 is estimated to be $13.6 million
  - Result: preliminary results
  source text: the Company disclosed in the Release preliminary estimates as to net product revenue for the quarter and year ended December 31, 2022 and cash and cash equivalents as of December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923001710/0001104659-23-001710-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.